-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027

Reuters·09/29/2026 06:38:42

Please log in to view news